TME Webinar: Extended Half-Life Factor VIII Agents in Hemophilia A: Evaluating the Evidence and Integration Strategies
Thursday, April 25, 2019 | 7:00 – 8:00 pm EDT
EDUCATIONAL GRANT SUPPORT
This educational activity is supported by an independent medical educational grant from Shire.
This activity is designed for US-based healthcare professionals, including hematologists, nurse practitioners (NPs), physician assistants (PAs), registered nurses, pharmacists, and other allied health professionals.
Extended half-life (EHL) rFVIII agents may alleviate some of the burdens associated with prophylactic treatment in hemophilia A. Their potential to decrease and better accommodate dosing regimens are a major step forward to optimize outcomes for these patients, and they have been shown in several clinical trials to be efficacious in controlling bleeding in both children and adults. Several EHL-rFVIII agents are approved for the treatment of hemophilia A and many more are in development. This educational webinar, led by expert Steven Pipe, MD, will review the latest clinical trial data about their efficacy and safety, as well as how to effectively incorporate these new agents in clinical practice.
After completing this activity, the participant should be better able to:
- Identify the rationale for the use of EHL-rFVIII agents in hemophilia A management
- Interpret the latest updates in clinical trial data using EHL-rFVIII agents in hemophilia A, including efficacy, safety, and dosing regimens
- Review practical strategies to incorporate EHL-rFVIII agents in hemophilia A treatment, including appropriate patient selection, transitioning from a standard FVIII therapy, and pharmacokinetic considerations in order to optimize patient outcomes
- Develop individualized treatment regimens for patients with hemophilia A based on the latest evidence about current and new prophylactic therapies, including EHL-rFVIII agents
Steven Pipe, MD
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI
I. Welcome and Introductions 7:00 – 7:05 pm
II. Hemophilia A – The Current State 7:05 – 7:10 pm
III. The Rationale and Evidence for EHL-rFVIII 7:10 – 7: 35 pm
IV. Patient Case Discussion 7:35 – 7:50 pm
V. Conclusions and Audience Q&A 7:50 – 8:00 pm
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and TME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19-761-L01-P.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Dr. Pipe discloses the following:
Consulting Fees: Apcintex, Bayer, Biomarin, Bioverative, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sanofi, Shire, Spark Therapeutics, uniQure
Planners and Managers
The PIM planners and managers have nothing to disclose. The TME planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
REQUEST FOR CREDIT
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14243. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Please complete the evaluation on http://www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14243. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.
There is no registration fee for this educational activity.